Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Hunting Disease In The Dark: MEDomics Seeks to Treat Mitochondrial Disease Before It Occurs
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Oncology Panel Selected in OneMedForum SF 2011
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
Blood Tests Can Enable Early Cancer Diagnosis
Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.
Molecular Diagnostics a Natural Fit for Breast Cancer
The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
